Gore ME - Search Results

1

New drug therapies for advanced renal cell carcinoma.

Gore ME, Harrison ML, Montes A. Gore ME, et al. Expert Rev Anticancer Ther. 2007 Jan;7(1):57-71. doi: 10.1586/14737140.7.1.57. Expert Rev Anticancer Ther. 2007. PMID: 17187520 Review.

2

Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose.

Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, Chao D, Hall K, Lee C, Timotheadou E, Charles K, Ahern R, King DM, Eisen T, Corringham R, DeWitte M, Balkwill F, Gore M. Harrison ML, et al. J Clin Oncol. 2007 Oct 10;25(29):4542-9. doi: 10.1200/JCO.2007.11.2136. J Clin Oncol. 2007. PMID: 17925549 Clinical Trial.

3

Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials.

Harrison ML, Gore ME, Spriggs D, Kaye S, Iasonos A, Hensley M, Aghajanian C, Venkatraman E, Sabbatini P. Harrison ML, et al. Among authors: gore me. Gynecol Oncol. 2007 Sep;106(3):469-75. doi: 10.1016/j.ygyno.2007.05.008. Epub 2007 Jul 5. Gynecol Oncol. 2007. PMID: 17614127 Free PMC article.

4

Mucinous ovarian cancer.

Harrison ML, Jameson C, Gore ME. Harrison ML, et al. Among authors: gore me. Int J Gynecol Cancer. 2008 Mar-Apr;18(2):209-14. doi: 10.1111/j.1525-1438.2007.01022.x. Epub 2007 Jul 11. Int J Gynecol Cancer. 2008. PMID: 17624989 Review.

5

Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy.

Han LY, Karavasilis V, Hagen Tv, Nicum S, Thomas K, Harrison M, Papadopoulos P, Blake P, Barton DP, Gore M, Kaye SB. Han LY, et al. Eur J Cancer. 2010 May;46(8):1359-64. doi: 10.1016/j.ejca.2010.02.012. Epub 2010 Mar 19. Eur J Cancer. 2010. PMID: 20303743

6

Evidence that multiple myeloma may be regulated by homeostatic control mechanisms: correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response.

Maitland JA, Millar BC, Bell JB, Montes A, Treleaven J, Gore ME, McElwain TJ. Maitland JA, et al. Among authors: gore me. Br J Cancer. 1990 Mar;61(3):429-33. doi: 10.1038/bjc.1990.94. Br J Cancer. 1990. PMID: 2328211 Free PMC article.

7

Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.

Gore ME, Larkin JM. Gore ME, et al. Br J Cancer. 2011 Feb 1;104(3):399-406. doi: 10.1038/sj.bjc.6606084. Br J Cancer. 2011. PMID: 21285971 Free PMC article. Review.

8

Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma.

Gore ME, Escudier B. Gore ME, et al. Oncology (Williston Park). 2006 May;20(6 Suppl 5):19-24. Oncology (Williston Park). 2006. PMID: 16773841 Free article. Review.

9

Imaging in metastatic renal cell carcinoma.

Griffin N, Gore ME, Sohaib SA. Griffin N, et al. Among authors: gore me. AJR Am J Roentgenol. 2007 Aug;189(2):360-70. doi: 10.2214/AJR.07.2077. AJR Am J Roentgenol. 2007. PMID: 17646462 Review.

10

Drug insight: advances in renal cell carcinoma and the role of targeted therapies.

Larkin JM, Chowdhury S, Gore ME. Larkin JM, et al. Among authors: gore me. Nat Clin Pract Oncol. 2007 Aug;4(8):470-9. doi: 10.1038/ncponc0901. Nat Clin Pract Oncol. 2007. PMID: 17657252 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

221 results

Search Page

Filters